Navigation Links
Roxane Laboratories, Inc. Announces the Approval of Morphine Sulfate Tablets and Oral Solution
Date:7/14/2008

COLUMBUS, Ohio, July 14 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the approval of its New Drug Application (NDA) for Morphine Sulfate Tablets and Oral Solution CII by the U.S. Food and Drug Administration. Roxane Laboratories' Morphine Sulfate CII is available in 15mg, 30mg tablet strengths and 10mg/5mL, 20mg/5mL oral solution strengths. Roxane Laboratories' Morphine Sulfate tablets and oral solutions CII are currently available for immediate shipment to wholesalers and pharmacies nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO )

With this New Drug Application approval, Roxane Laboratories has the only FDA approved Morphine Sulfate Immediate Release Tablets and Oral Solution available for distribution in the United States.

Full prescribing information for Morphine Sulfate is available on the Roxane Laboratories website at http://www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 75 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to se
'/>"/>

SOURCE Roxane Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
2. Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg
3. Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg
4. Roxane Laboratories, Inc. Announces the Launch of Acarbose Tablets
5. Roxane Laboratories, Inc. Announces the Launch of Ramipril Capsules
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
11. Getting Ready Corporation and Winston Laboratories, Inc. Announce Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...developed a way to produce blood vessels by engine... Researchers at the University at Buffalo D...y that the bone marrow is an excellent source of a... applications. According to Dr. Stelios T....
...e University of Nottingham are amassing an arsenal... against the most deadly of hospital superbugs . .... Its defences are so strong it can resist most an...hcare Associated Infections (CHAI), with Dr Peter ...
...niversity researcher is experimenting with ways to...hat we like about our favourite snacks . S...nce and industry at K-State's College of Agricultu... this process can be used to make fibre-enriched f...
...found that women are the real bosses at home . ...s, wives have greater power in marriage problem-so... 72 married couples from Iowa, found that wives, o... not considering who raised the topic. As...
...ting dads will be given some tips on how to raise ... The British government is hoping that its 23milli...et technology to support parents will appeal to fa...w initiative, "Parent Know-How", parents will be a...
...ho killed his 25-year-old female neighbor was sent...of Alicia Ross by her neighbor Daniel Sylvester w...ousness, by an Ontario Superior Court judge who im...er in the death of Alicia Ross, intended to kill h...
Other Medicine News:Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2Health News:The Hospital Superbugs 2Health News:The Hospital Superbugs 3Health News:Now, Fibre-enriched Tasty Snacks in the Making 2Health News:Women are the Real Bosses at Home 2Health News:Women are the Real Bosses at Home 3Health News:A Savage Murderer in Canada Gets Sentenced to Life 2
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Omega 3 fatty acids appear to impact AMD progression 8896 1Omega 3 fatty acids appear to impact AMD progression 8896 2Omega 3 fatty acids appear to impact AMD progression 8896 3The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 1The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 1Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 3
... SUNNYVALE, Calif., April 13 Pharmacyclics, In...egun treating patients in a Phase,1 dose-escalatio... PCI-32765,an orally available, selective inhibito...al treatment for patients with relapsed or refract... the first Btk selective inhibitor to,be tested in...
... NOVATO, Calif., April 13 Raptor Pharmaceuticals ...ard: RPTP) today announced the appointment of Patr...r ("CMO"). Dr. Rioux will be responsible for the c...nical-stage drug development programs. , , (Logo:...YM074LOGO ) , , Raptor,s clinical programs inc...
Other Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 2Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 3Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 4Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 5
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
Medicine Products: